应用大剂量强化治疗延长急性白血病患者缓解期和生存期  

The Prolongation of the Remission Duration and Surrival of the Patients with Acute Leukemia Using High Dose Intensive Chemotherapy

作　　者：乔振华[1] 王椿[1] 杨林花 马梁明 张金梅[1] 吕家瀛 蕲锁桃 张辉[1] 刘澜 冉家彦[1] 

机构地区：[1]山西医学院第二附属医院血液内科,030001

出　　处：《临床血液学杂志》1993年第2期54-57,共4页Journal of Clinical Hematology

摘　　要：采用大剂量阿糖胞苷及柔红霉素(HD-AD)治疗缓解急性髓系白血病(AML)22例,大剂量氨甲喋呤及左旋门冬酰胺酶(HD-MA)治疗缓解期急性淋巴细胞白血病(ALL)8例。使AML和ALL的平均缓解期分别达到26.6月和32.5月,明显优于一般巩固化疗效果(分别为11.6月和7.0月),2年以上的生存率达57%,3年以上者27%,表明大剂量化疗用于急性白血病的巩固治疗是延长缓解期和生存期的有效措施之一。High-dose cytorabine(Ara-C) and daunorubicin were administered to treat 22cases with acute myeloid leukemia(AML) in remission, and high-dose methortexate and L-as-paraginase were administered to treat 8 cases with acute lymphoblastic leukemia (ALL) in re-mission. The median duration of remission of AML and ALL patients receiving high-dosechemotherapy were 26.6 and 32.5 months, respectively, which were superior to that of the pa-tients receiving conventional consolidation therapy, 11.6 and 7.0 months, respectively. The in-tensive regimens resulted in asignificantly improved 2- and 3-year survial of 67% and 27% ver-sus 17% and 7% for the conventional ones. It was demonstrated that intensive postremissionconsolidation therapy is a practical and effective approach to prolong remission duration and sur-vival of teh patients with acute ieukemia.

关 键 词：白血病 生存期 药物疗法 

分 类 号：R733.7[医药卫生—肿瘤]